WO2025169146 - CD40 ANTAGONIST OR CD154 ANTAGONIST FOR USE IN MITIGATING IMMUNE RESPONSES IN PROTEIN AND GENE THERAPIES
National phase entry is expected:
Publication Number
WO/2025/169146
Publication Date
14.08.2025
International Application No.
PCT/IB2025/051326
International Filing Date
07.02.2025
Title **
[English]
CD40 ANTAGONIST OR CD154 ANTAGONIST FOR USE IN MITIGATING IMMUNE RESPONSES IN PROTEIN AND GENE THERAPIES
[French]
ANTAGONISTE DE CD40 OU ANTAGONISTE DE CD154 DESTINÉ À ÊTRE UTILISÉ DANS L'ATTÉNUATION DE RÉPONSES IMMUNITAIRES DANS DES THÉRAPIES PROTÉIQUES ET GÉNIQUES
Applicants **
KINIKSA PHARMACEUTICALS, GMBH
Inventors
PAOLINI, John F.
TESSARI, Eben
ATAMAS, Sergei
Priority Data
63/551,977
09.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2906 | |
| EPO | Filing, Examination, Granting | 20952 | |
| Japan | Filing, Examination, Granting | 2923 | |
| South Korea | Filing, Examination, Granting | 3370 | |
| USA | Filing, Examination, Granting | 8340 |
Total:
38,491
Abstract[English]
Featured are the use of pharmaceutical compositions containing a CD40 antagonist or a CD154 antagonist for the treatment, reduction, and/or inhibition of an immune response, such as an anti-drug antibody response, following, e.g., protein replacement therapy or gene therapy.[French]
L'invention concerne l'utilisation de compositions pharmaceutiques contenant un antagoniste de CD40 ou un antagoniste de CD154 pour le traitement, la réduction et/ou l'inhibition d'une réponse immunitaire, telle qu'une réponse d'anticorps anti-médicament, après, par exemple, une thérapie de remplacement de protéines ou une thérapie génique.